Validation of the MiCK Assay
Testing Mayo Clinic cancer patients with the results being correlated with prior patient therapy, performance status, and extent of disease.
Mesothelioma, Small Cell Lung Cancer, NSCLC
|Study Type:||Observational [Patient Registry]|
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Target Follow-Up Duration:||1 Year|
|Official Title:||Mayo Clinic Validation of the MiCK Assay|
- Complete response and survival [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
Human cancerous tumor.
|Study Start Date:||June 2012|
|Estimated Study Completion Date:||March 2015|
|Estimated Primary Completion Date:||December 2014 (Final data collection date for primary outcome measure)|
|all cancer types|
This study will be conducted in two phases.
During the Feasibility Phase, specimens from any tumor will be sent to the central DiaTech MiCK assay laboratory to determine the ease of sample acquisition, processing, transport, and assay interpretation.
Once DiaTech has completed analyses for the feasibility phase specimens and has confirmed that the sample acquisition, processing, transport, and assay interpretation are appropriate, we will proceed with the Demonstration Phase.
During the Mesothelioma Demonstration Phase, 20 mesothelioma samples will be assayed and the results will be correlated with prior patient therapy, performance status, and extent of disease.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01770665
|Contact: Mary Karausfirstname.lastname@example.org|
|United States, Minnesota|
|Mayo Validation Support Services 3050 Superior Drive NW||Recruiting|
|Rochester, Minnesota, United States, 55901|
|Contact: Mary Karaus 507-538-8472 email@example.com|
|Principal Investigator: Julian Molina, MD, PhD|
|Principal Investigator: Dennis Wigle, MD, PhD|
|Study Director:||Mary Karaus||Mayo Clinic|